Ladan Mehran

Scopus Publications

Long-term natural history of thyroid peroxidase antibodies in a population-based cohort: Findings from 18 years of follow-up in Tehran Thyroid Study (TTS)
Mohamadamin Tarighat-Payma, Ladan Mehran, Safdar Masoumi, Maryam Tohidi, Atieh Amouzegar, Fereidoun Azizi, Elizabeth N. Pearce
Journal of Translational Autoimmunity, 2026
Background: Thyroid peroxidase antibody (TPOAb) is considered a highly sensitive marker of autoimmune thyroid diseases (AITD). Limited longitudinal data exist regarding its long-term natural history in the general population. This study aimed to assess risk factors for TPOAb positivity and its 18-year prevalence, incidence, trajectories, and projected prevalence for the year 2030 in a population-based cohort. Methods: A total of 5,438 adults were recruited at first visit (1999-2002) and followed across four subsequent visits up to 2018 in the iodine-sufficient population-based Tehran Thyroid Study (TTS). The age- and sex-standardized prevalence of TPOAb positivity was calculated, and the projected prevalence in 2030 was estimated using Poisson Generalized Linear Mixed Model (Poisson GLMM). Longitudinal trajectories of TPOAb were identified using latent class growth mixture model (LCGMM). Cox proportional hazards models were used to examine associations between potential risk factors and TPOAb positivity. Results: The prevalence increased progressively from 11.7% at the first visit (1999-2002) to 16.3% at the fifth visit (2015-2018), and is projected to reach 21.04% in 2030. Four distinct TPOAb trajectories were identified: Low-stable (81.4%), Low-increasing (2.9%), High-decreasing (2.4%), and High-stable (13.3%). The overall incidence rate of TPOAb positivity was 5.6 per 1,000 person-years, higher among women and individuals aged <40 years. In multivariable analysis, female sex (Hazard Ratio (HR) = 1.61; 95% CI: 1.15-2.27) and elevated TSH ≥5 mU/L (HR = 2.69; 95% CI: 1.57-4.63) were significant positive predictors of TPOAb positivity, while age between 40 and 60 years was inversely associated with incident TPOAb positivity (HR = 0.71; 95% CI: 0.55-0.90). Conclusions: This is the first and longest study worldwide that demonstrated a persistent rise in TPOAb positivity across five repeated measurements in an iodine-sufficient population, driven by female sex, age <40, and TSH ≥5 mU/L, which is projected to reach 21.04% in 2030. Trajectory patterns of TPOAb showed that the majority of participants had consistently low-stable levels of TPOAb.
Trends in the incidence and prevalence of thyroid dysfunction over 18 years and projections for 2030: the Tehran thyroid study
Narges Bagherian, Ladan Mehran, Hengameh Abdi, Safdar Masoumi, Maryam Tohidi, Mohammadjavad Honarvar, Atieh Amouzegar, Fereidoun Azizi
Journal of Diabetes and Metabolic Disorders, 2026
Beyond Salt Iodization: Sustained Population Sufficiency and Recurrence of Iodine Deficiency in Pregnant Women in Iran
Ladan Mehran, Atieh Amouzegar, Safdar Masoumi, Mehdi Hedayati, Parvin Mirmiran, Mohamadamin Tarighat-Payma, Golshan Amirshekari, Fereidoun Azizi
Thyroid Official Journal of the American Thyroid Association, 2026
Background: Iodine deficiency disorders (IDDs) remain a public health concern, especially in pregnancy, despite universal salt iodization (USI) programs. Iran has sustained iodine sufficiency since the 1990s through national USI, but recent evidence suggests recurrent iodine insufficiency among pregnant women. This study reports findings from the sixth National Monitoring Survey (2022–2023) to reassess iodine status in schoolchildren and pregnant women in Iran. Methods: This cross-sectional survey included 11,221 schoolchildren aged 8–10 years and 2929 pregnant women from all 31 provinces. Multistage cluster sampling ensured national representativeness for children. At the same time, pregnant women were recruited from health centers by equal provincial quotas (60 per province, not population-weighted), and their individual intake of iodide along with folic acid supplements was documented. Urinary iodine concentration (UIC) was measured using the Sandell–Kolthoff method, and salt iodine content was assessed by iodometric titration at production and household levels. Data were analyzed with descriptive and nonparametric statistical methods. Results: The median UIC in schoolchildren was 133 µg/L (interquartile range [IQR]: 88–183), within the World Health Organization (WHO)-recommended range, with 67.7% having UIC ≥100 µg/L. However, 22.8% had a UIC of 50–100 µg/L and 9.5% <50 µg/L. In pregnant women, the median UIC was 128 µg/L (IQR: 84–187), below the WHO threshold of 150 µg/L, with 61.2% having UIC <150 µg/L and 34.4% <100 µg/L. 73.7% of pregnant women used iodide + folic acid supplement, with wide provincial variation of 38–84%. Household salt median iodine content was 32 ppm, but 30.6% of samples were <20 ppm, and only 54% were stored properly. Production-level salt had a median iodine content of 33.8 ppm. Conclusions: Although Iran has maintained iodine sufficiency in the general population during the last three decades, mild iodine deficiency has reappeared among pregnant women due to incomplete usage of iodide folic acid supplementation. Strengthened monitoring, stricter quality assurance in salt production, improved adherence to iodine supplementation in pregnant women, and targeted provincial interventions are needed to sustain IDD elimination.
Sustained Control of Hyperthyroidism in Graves’ Disease: Comparison of Thyroidectomy and Long-Term Antithyroid Treatment
Hengameh Abdi, Miralireza Takyar, Ladan Mehran, Safdar Masoumi, Atieh Amouzegar, Fereidoun Azizi
International Journal of Endocrinology and Metabolism, 2026
Background: The achievement of sustained euthyroidism in patients with Graves’ hyperthyroidism may reduce the risk of mortality and cardiovascular events. Objectives: We compared the time to euthyroidism and the time remaining in euthyroidism following total thyroidectomy and long-term methimazole (LT-MMI) treatment. Methods: In this prospective cohort study, two hundred and eight patients with diffuse toxic goiter, 104 (84 women) with total thyroidectomy, and 104 (84 women) on LT-MMI were compared. All patients received adequate levothyroxine treatment after thyroidectomy. Data on serum free thyroxine (fT4), triiodothyronine (T3), and thyrotropin (TSH) every 6 months until the end of follow-up were analyzed. The time to normalization of serum thyroid hormones and TSH concentrations and the percentage of time that thyroid hormones and TSH levels remained within the normal range during a mean follow-up of 11 years were compared between the two study groups using t-test, Mann-Whitney U, chi-square, and Fisher exact tests. Results: The mean time to euthyroidism was 4.74 ± 2.42 and 4.48 ± 2.54 months in the thyroidectomy and LT-MMI groups, respectively. During follow-up, the percentage of time spent in euthyroidism was 82.67 ± 7.33% vs 94.21 ± 6.98% in the thyroidectomy and LT-MMI groups, respectively (P < 0.001). Patients with thyroidectomy spent more time in subclinical and clinical hypo- and hyperthyroidism compared to LT-MMI patients. Permanent hypocalcemia and vocal cord paralysis occurred in 2 and 1 patients, respectively. Conclusions: Treatment of hypothyroidism after total thyroidectomy was accompanied by less sustained euthyroidism during long-term follow-up compared with LT-MMI therapy. This difference may be important for the risk of mortality and cardiovascular events, demanding long-term studies for comparison of these outcomes in patients treated with total thyroidectomy and LT-MMI treatment.
Thyroid Hormones and Metabolic Syndrome: A Narrative Review of Findings from 18 Years of Follow-up in Tehran Thyroid Study (TTS)
Atieh Amouzegar, Mohamadamin Tarighat-Payma, Safdar Masoumi, Alireza Amirabadizadeh, Hengameh Abdi, et al.
International Journal of Endocrinology and Metabolism, 2026
Context: Thyroid dysfunction and metabolic syndrome (MetS) share similar pathophysiological features, suggesting a bidirectional relationship between these two prevalent endocrinological disorders. This review summarizes findings from 18 years of follow-up in the Tehran Thyroid Study (TTS), a large community-based prospective cohort, focusing on the association between thyroid function and MetS. Evidence Acquisition: We systematically reviewed TTS publications (until 2025) on thyroid function and MetS. Exposures included thyroid-stimulating hormone (TSH), free thyroxine (FT4), thyroid peroxidase antibody (TPOAb), and thyroid feedback indices [Thyroid Feedback Quantile-Based Index (TFQI), Thyrotroph T4 Resistance Index (TT4RI), and TSH Index (TSHI)]. Outcomes were MetS and its components. Study designs ranged from cross-sectional and prospective cohort to joint longitudinal/time-to-event models. Results: Cross-sectional TTS analyses showed an inverse association between FT4 (but not TSH) and the prevalence of MetS. Among 3,755 euthyroid adults, a 1-unit increase in FT4 was associated with lower odds of MetS (OR 0.96, 95% CI: 0.92 - 0.99). Across thyroid functional states, overt hypothyroidism had the highest MetS prevalence (41.6%); in men, overt hypothyroidism was associated with higher odds of MetS versus euthyroidism (OR 2.9, 95% CI: 1.04 - 8.40). Prospective TTS analyses supported a modest thyroid-to-MetS direction. In a 10-year cohort of 2,393 participants without MetS at baseline, declining FT4 over follow-up predicted incident MetS in non-obese adults (OR 0.57, 95% CI: 0.34 - 0.96) and was associated with lower odds of incident abdominal obesity and hypertriglyceridemia. In joint longitudinal-time-to-event models (n = 1,436; median 9-year follow-up), higher time-varying TSH was associated with higher MetS risk (HR 1.17, 95% CI: 1.01 - 1.28), while higher FT4 predicted lower MetS risk (HR 0.54, 95% CI: 0.29 - 0.97). In the reverse direction, baseline MetS did not independently predict incident thyroid dysfunction over 9 years (n = 4,905; adjusted HR, 0.95; 95% CI: 0.77 - 1.18). Thyroid hormone sensitivity indices were not associated with MetS overall, although higher TFQI was associated with hypertension (OR 1.14, 95% CI: 1.05 - 1.23). Conclusions: Eighteen years of follow-up in TTS suggest a modest, mostly one-way thyroid-MetS association. Higher (or high-normal) TSH and lower FT4 modestly increase MetS risk, whereas baseline MetS did not significantly increase the risk of later thyroid dysfunction.
Evaluating the association between TSH and FT4 levels and the incidence of metabolic syndrome: insights from the Tehran thyroid study using joint modeling
Alireza Amirabadizadeh, Ladan Mehran, Atieh Amouzegar, Samaneh Asgari, Fereidoun Azizi
Scientific Reports, 2025
This study aims to investigate the longitudinal association between thyroid-stimulating hormone (TSH), free thyroxine (FT4), and the incidence of metabolic syndrome (MetS) using joint modeling techniques over a ten-year follow-up in the Tehran Thyroid Study (TTS). Data from 1436 participants aged 20 years or older in the TTS cohort were analyzed. The study spanned four years, beginning in 1999 and concluding in 2012, with follow-up assessments conducted every three years. Longitudinal changes in logarithm-transformed TSH and FT4 levels were examined as time-varying exposures to evaluate their association with the incidence of metabolic syndrome (MetS). Over a median follow-up of 8.92 years, 574 new MetS cases were identified. Higher TSH levels were positively associated with MetS risk (HR: 1.17, 95%CI: 1.03-1.33), while higher FT4 levels were inversely associated with MetS risk (HR: 0.54, 95%CI: 0.29-0.97). Higher TSH levels also correlated with an increased risk of hypertension, while higher FT4 levels were linked to a reduced risk of abdominal obesity and hypertriglyceridemia. Our study highlights the association between thyroid hormone changes and the development of MetS, utilizing joint modeling of longitudinal and time-to-event data over a ten-year follow-up. The observed shift toward hypothyroidism, characterized by increasing TSH and declining FT4 levels, emphasizes the importance of regular thyroid function monitoring as part of MetS prevention and management strategies.
Medical Treatment of Hyperthyroidism; Efficacy and Safety Considerations
Fereidoun Azizi, Hengameh Abdi, Seyed Alireza Ebadi, Ladan Mehran, Atieh Amouzegar
Archives of Iranian Medicine, 2025
Antithyroid drugs (ATDs) are often the first treatment option for hyperthyroidism due to their efficacy and safety profile. Long-term ATD treatment can effectively control hyperthyroidism and prevent relapse. In this review, we summarize the findings of clinical trials and clinical experiences on the use of ATD treatment for hyperthyroidism. We discuss the efficacy and safety of ATD treatment, as well as the optimal duration of treatment. The evidence suggests that ATD therapy is selected as initial therapy, treatment of relapse of hyperthyroidism and in patients with persistent elevation of TSH receptor antibodies after 18 months of ATD therapy. Long-term ATD treatment can be an effective and safe option for management of many patients with hyperthyroidism. However, additional studies are needed to establish the most efficacious treatment duration and to identify patients who are most likely to benefit from long-term ATD treatment.
Trajectory Patterns of Metabolic Syndrome Severity Score and Risk of Chronic Kidney Diseases
Ladan Mehran, Atefeh Amouzegar, Safdar Masoumi, Maryam Adib, Fereidoun Azizi, Atieh Amouzegar
Kidney Diseases, 2025
Introduction: Despite the reported connection between different combinations of the standard MetS criteria and chronic kidney diseases (CKDs), most data raise significant concerns about its predictive usefulness in clinical settings beyond its components. Metabolic syndrome severity, expressed by the continuous metabolic syndrome severity score (cMetS-S), is a more applicable health metric that may more accurately predict future health outcomes. However, no evidence is known about the association between the trajectory of cMetS-S and the development of CKD. Methods: In the population-based Tehran Lipid and Glucose Study, 4,462 participants aged 20–60 years free of CKD at baseline were included and followed at 3-year intervals. We examined the trajectories of cMetS-S over 9 years (1999–2009) using latent growth mixture modeling and subsequent risks of incident CKD 8 years later (2010–2018). The prospective association of identified trajectories with CKD was examined using the Cox proportional hazard model adjusting for age, sex, education, and family history of diabetes, physical activity, obesity (BMI ≥30 kg/m2), antihypertensive, and lipid-lowering medication, and baseline fasting plasma glucose in a stepwise manner. Results: Three cMetS-S trajectory groups of low (28.3%), medium (50.0%), and high (21.7%) were identified during the exposure period. High cMetS-S trajectory pattern was associated with increased risk of CKD adjusting for age, sex, education, smoking, physical activity, baseline estimated glomerular filtration rate, and even after further adjustment for MetS components (1.32; 95% CI: 1.04–1.67). The associated risk remained significant even in normoglycemic, nonobese, and non-hypertensive individuals. Sex-specific subgroup analysis showed that MetS severity score is associated with CKD only in men. Conclusion: The trend of cMetS-S over time is associated with the development of CKD, even in those without major risk factors, for example, obesity, diabetes mellitus, and hypertension. It could be clinically helpful in identifying individuals at elevated risk rather than stating it as a predictive or causative factor. It could be clinically beneficial in identifying and tracking individuals at elevated risk rather than stating it as a predictive or causative factor.
Treatment of hypothyroidism with levothyroxine plus slow-release liothyronine: a study protocol for a randomized controlled double-blinded clinical trial
F. Azizi, A. Amouzegar, H. Abdi, M. Tohidi, S. Masoumi, et al.
Trials, 2025
BACKGROUND: There are emerging controversies regarding the priority of T4 + T3 combination therapy over standard care with levothyroxine (LT4) monotherapy in the management of hypothyroid subjects. Combination therapy with a slow-release form of liothyronine (SRT3) and levothyroxine may restore T3 concentrations and provide better outcomes, especially in individuals with persistent complaints despite having normal serum TSH levels. METHODS: One hundred patients aged ≥ 20 years with hypothyroidism who have achieved and maintained euthyroidism under LT4 monotherapy for at least 3 months will be randomized into two groups of LT4 + SRT3 combined therapy (75 µg LT4 + 25 µg SRT3) and LT4 monotherapy for 48 weeks. Participants will be evaluated at baseline and three subsequent follow-ups, 12, 24, and 48 weeks after treatment allocation. Before and after the intervention, body weight, heart rate, blood pressure, ECG, quality of life (by ThyPRO-39 and SF-12), resting energy expenditure, and body composition will be evaluated. Also, serum TSH, total T3, total T4, free T4, free T3, total cholesterol, LDL, HDL, triglycerides, fasting blood sugar (FBS), insulin, HbA1C, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), sex hormone-binding globulin (SHBG), enolase, lactate dehydrogenase (LDH), creatin kinase (CK), ferritin, and metabolomics will be assessed at baseline and compared with their corresponding values at 24 and 48 weeks. Epigenetic-related markers will be measured and compared between the responders and non-responders. CONCLUSION: It is expected that LT4 + SRT3 combined therapy more closely mimics the serum levels of T3, T4, and the T3/T4 ratio of euthyroid subjects than LT4 monotherapy, and improves health outcomes and quality of life, especially in hypothyroid patients with persistent symptoms under LT4 monotherapy. Genetic polymorphism sequencing may identify hypothyroid patients who are not responding well to levothyroxine alone. TRIAL REGISTRATION : Trial ID: 44220 ID: IRCT20100922004794N12 IRCT ID: IRCT20100922004794N12 Registration date: 2020-02-27 Expected recruitment start date: 2024-10-06 Expected recruitment end date: 2025-10-23.
Exploring the bidirectional association between thyrotropin and thyroid hormones in type 2 diabetes: a systematic review and meta-analysis
Alireza Amirabadizadeh, Alireza Ghorbani, Fereidoun Azizi, Hengameh Abdi, Atieh Amouzegar, Ladan Mehran
Journal of Diabetes and Metabolic Disorders, 2025
Treatment of hypothyroidism with the combination of levothyroxine and slow-release triiodothyronine: a randomized clinical trial
F. Azizi, A.S. Moeini, L. Mehran, S. Masoumi, H. Abdi, S.M. Foroutan, A.E. Saghafinia, A. Amouzegar
Journal of Clinical and Translational Endocrinology, 2025
Treatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy
Fereidoun Azizi, Atieh Amouzegar, Hengameh Abdi, Safdar Masoumi, Ladan Mehran
Endocrine Metabolic and Immune Disorders Drug Targets, 2025
Association between central thyroid hormone sensitivity and prediabetes: Tehran thyroid study
Ladan Mehran, Mohammadjavad Honarvar, Maryam Tohidi, Maryam Adib, Fereidoun Azizi, Atieh Amouzegar
Frontiers in Endocrinology, 2025
Interrelationship between thyroid hormones and reduced renal function, a review article
Sadaf Agahi, Atieh Amouzegar, Mohammadjavad Honarvar, Fereidoun Azizi, Ladan Mehran
Thyroid Research, 2024
Association between body mass index trajectories and type 2 diabetes incidence over an 18-year follow-up in the Tehran Lipid and Glucose Study
Nafiseh Hassanloo, Ladan Mehran, Atieh Amouzegar, Hengameh Abdi, Safdar Masoumi, Fereidoun Azizi, Seyede Parmis Maroufi
Scientific Reports, 2024
Optimal Cut-off Points of the Standardized Continuous Metabolic Syndrome Severity Score (cMetS-S) for Predicting Cardiovascular Disease (CVD) and CVD Mortality in the Tehran Lipid and Glucose Study (TLGS)
Maryam Adib, Ladan Mehran, Safdar Masoumi, Iman Vatanpoor, Fereidoun Azizi, Atieh Amouzegar
International Journal of Endocrinology and Metabolism, 2024
Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease
Fereidoun Azizi, Ladan Mehran, Hengameh Abdi, Atieh Amouzegar
Journal of Clinical Endocrinology and Metabolism, 2024
Independent association of metabolic syndrome severity score and risk of diabetes: findings from 18 years of follow-up in the Tehran Lipid and Glucose Study
Atieh Amouzegar, Mohmmadjavad Honarvar, Safdar Masoumi, Sadaf Agahi, Fereidoun Azizi, Ladan Mehran
BMJ Open, 2024
Vitamin D and Anti-thyroid Peroxidase Antibody: Tehran Thyroid Study
Iranian Journal of Endocrinology and Metabolism, 2024
Association between changes in thyroid hormones and incident type 2 diabetes using joint models of longitudinal and time-to-event data: more than a decade follow up in the Tehran thyroid study
Alireza Amirabadizadeh, Ladan Mehran, Atieh Amouzegar, Samaneh Asgari, Davood Khalili, Fereidoun Azizi
Frontiers in Endocrinology, 2024
The association of body mass index variability with cardiovascular disease and mortality: a mediation analysis of pooled cohorts
Ladan Mehran, Mohammadjavad Honarvar, Safdar Masoumi, Davood Khalili, Fereidoun Azizi, Michael J. Blaha, Atieh Amouzegar
Frontiers in Endocrinology, 2024
The effect of metformin therapy on serum thyrotropin and free thyroxine concentrations in patients with type 2 diabetes: a meta-analysis
Alireza Amirabadizadeh, Atieh Amouzegar, Ladan Mehran, Fereidoun Azizi
Scientific Reports, 2023
Cardiometabolic-related dietary patterns and thyroid function: a population-based cross-sectional study
Nazanin Moslehi, Saba Mohammadpour, Parvin Mirmiran, Ladan Mehran, Fereidoun Azizi
European Journal of Medical Research, 2023
Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study
Mohammadjavad Honarvar, Safdar Masoumi, Ladan Mehran, Davood Khalili, Atieh Amouzegar, Fereidoun Azizi
Scientific Reports, 2023
Trajectory patterns of metabolic syndrome severity score and risk of type 2 diabetes
Atieh Amouzegar, Mohammadjavad Honarvar, Safdar Masoumi, Davood Khalili, Fereidoun Azizi, Ladan Mehran
Journal of Translational Medicine, 2023
Independent association between age- and sex-specific metabolic syndrome severity score and cardiovascular disease and mortality
Mohammadjavad Honarvar, Ladan Mehran, Safdar Masoumi, Sadaf Agahi, Shayesteh Khalili, Fereidoun Azizi, Atieh Amouzegar
Scientific Reports, 2023
Pharmacodynamic and pharmacokinetic properties of the combined preparation of levothyroxine plus sustained- release liothyronine; a randomized controlled clinical trial
Ladan Mehran, Atieh Amouzegar, Seyed Mohsen Foroutan, Safdar Masoumi, Maryam Tohidi, Hengameh Abdi, Ali Aghaei, Amir Esmaeel Saghafinia, Fereidoun Azizi
BMC Endocrine Disorders, 2023
Assessing the Risk of Cardiovascular Diseases: Metabolic Syndrome Versus Quantitative Metabolic Syndrome Severity Score
Iranian Journal of Endocrinology and Metabolism, 2023
Sex-specific Trajectories of Insulin Resistance Markers and Reduced Renal Function During 18 Years of Follow-up: TLGS
Atieh Amouzegar, Mohammadjavad Honarvar, Safdar Masoumi, Maryam Tohidi, Ladan Mehran, Fereidoun Azizi
Journal of Clinical Endocrinology and Metabolism, 2023
The impact of metabolic syndrome on chronic kidney disease development. Insights from a big prospective study
Seyedeh Melika Fanaei, Ladan Mehran, Atieh Amouzegar, Safdar Masoumi, Atefeh Amouzegar, Freidoun Azizi
European Journal of Clinical Investigation, 2023
Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine
Fereidoun Azizi, Hengameh Abdi, Ladan Mehran, Petros Perros, Safdar Masoumi, Atieh Amouzegar
Endocrine Practice, 2023
Association of trajectory of body shape index with all-cause and cause-specific mortality: 18 years follow-up
Elham Kazemian, Ladan Mehran, Safdar Masoumi, Atieh Amouzegar, Fereidoun Azizi
Frontiers in Endocrinology, 2023
Weight fluctuation, mortality, and cardiovascular disease in adults in 18 years of follow-up: Tehran Lipid and Glucose Study
L. Mehran, M. Honarvar, S. Masoumi, D. Khalili, A. Amouzegar, F. Azizi
Journal of Endocrinological Investigation, 2023
Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in the Treatment of Toxic Multinodular Goiter
Fereidoun Azizi, Navid Saadat, Mir Alireza Takyar, Hengameh Abdi, Ladan Mehran, Atieh Amouzegar
Endocrinology and Metabolism, 2022
Natural history of subclinical hypothyroidism and prognostic factors for the development of overt hypothyroidism: Tehran Thyroid Study (TTS)
A. Amouzegar, M. Dehghani, H. Abdi, L. Mehran, S. Masoumi, F. Azizi
Journal of Endocrinological Investigation, 2022
BMI variability and incident diabetes mellitus, Tehran Lipid and Glucose Study (TLGS)
Ladan Mehran, Pouria Mousapour, Davood Khalili, Leila Cheraghi, Mohammadjavad Honarvar, Atieh Amouzegar, Fereidoun Azizi
Scientific Reports, 2022
Time to Normalization and Sustainable Normal Serum Thyrotropin Concentrations in Patients with Hyperthyroidism: Comparison of Methimazole and Radioactive Iodine Treatments
Fereidoun Azizi, Navid Saadat, Hengameh Abdi, Ladan Mehran, Safdar Masoumi, Mir Alireza Takyar, Atieh Amouzegar
Endocrine Practice, 2022
Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves’ disease: a systematic scoping review
F. Azizi, H. Abdi, L. Mehran, A. Amouzegar
Journal of Endocrinological Investigation, 2022
TPO antibody in euthyroid pregnant women and cognitive ability in the offspring: a focused review
A. Amouzegar, E. N. Pearce, L. Mehran, J. Lazarus, M. Takyar, F. Azizi
Journal of Endocrinological Investigation, 2022
Anthropometric measures and risk of all-cause and cardiovascular mortality: An 18 years follow-up
Ladan Mehran, Atieh Amouzegar, Seyedeh Melika Fanaei, Safdar Masoumi, Fereidoun Azizi
Obesity Research and Clinical Practice, 2022
Reduced Sensitivity to Thyroid Hormone Is Associated with Diabetes and Hypertension
Ladan Mehran, Negar Delbari, Atieh Amouzegar, Mitra Hasheminia, Maryam Tohidi, Fereidoun Azizi
Journal of Clinical Endocrinology and Metabolism, 2022
Investigating the prevalence of primary thyroid dysfunction in obese and overweight individuals: Tehran thyroid study
Mahdi Mahdavi, Atieh Amouzegar, Ladan Mehran, Elham Madreseh, Maryam Tohidi, Fereidoun Azizi
BMC Endocrine Disorders, 2021
Reciprocal Association between Thyroid Function and Metabolic Syndrome: A Review Article
Iranian Journal of Endocrinology and Metabolism, 2021
Trimester-Specific Reference Ranges for Free Thyroxine Hormone in Iranian Pregnant Women
Iranian Journal of Endocrinology and Metabolism, 2021
Development of a risk prediction model for early discrimination between permanent and transient congenital hypothyroidism
Ladan Mehran, Fereidoun Azizi, Pouria Mousapour, Leila Cheraghi, Shahin Yarahmadi, Golshan Amirshekari, Davood Khalili
Endocrine, 2021
Incidence of Thyroid Dysfunction Facing Metabolic Syndrome: A Prospective Comparative Study with 9 Years of Follow-Up
Ladan Mehran, Atieh Amouzegar, Hengameh Abdi, Negar Delbari, Elham Madreseh, Maryam Tohidi, Mohammad Ali Mansournia, Fereidoun Azizi
European Thyroid Journal, 2021
Cumulative Effects of Thyroid Hormones over 10 Years and Risk of General and Abdominal Obesity
Ladan Mehran, Atieh Amouzegar, Safoora Gharibzadeh, Hengameh Abdi, Mohammadali Mansournia, Maryam Tohidi, Fereidoun Azizi
Hormone and Metabolic Research, 2021
Erratum: Cumulative Effects of Thyroid Hormones over 10 Years and Risk of General and Abdominal Obesity (Horm Metab Res DOI: 10.1055/a-1393-5864)
Ladan Mehran, Atieh Amouzegar, Safoora Gharibzadeh, Hengameh Abdi, Mohammad Ali Mansournia, Maryam Tohidi, Fereidoun Azizi
Hormone and Metabolic Research, 2021
Determination of age and sex specific TSH and FT4 reference limits in overweight and obese individuals in an iodine-replete region: Tehran Thyroid Study (TTS)
Hengameh Abdi, Bita Faam, Safoora Gharibzadeh, Ladan Mehran, Maryam Tohidi, Fereidoun Azizi, Atieh Amouzegar
Endocrine Research, 2021
Parity and incidence of thyroid autoimmunity: A population-based tehran thyroid study
Miralireza Takyar, Maryam Rahmani, Atieh Amouzegar, Elham Madreseh, Maryam Tohidi, Ladan Mehran, Fereidoun Azizi
Thyroid, 2020
Determining the prognostic factors of permanent congenital hypothyroidism
Iranian Journal of Endocrinology and Metabolism, 2020
Isolated Hypothyroxinemia in Iranian Pregnant Women, the Role of Iodine Deficiency: A Population-Based Cross-Sectional Study
Ali Etemadi, Atieh Amouzegar, Ladan Mehran, Maryam Tohidi, Fereidoun Azizi, Kamyar Moradi, Hossein Delshad
Thyroid, 2020
LT4 and slow release T3 combination: Optimum therapy for hypothyroidism?
Fereidoun Azizi, Atieh Amouzegar, Ladan Mehran, Hengameh Abdi
International Journal of Endocrinology and Metabolism, 2020
Association between thyroid function and body mass index in tehran thyroid study population
Iranian Journal of Endocrinology and Metabolism, 2020
Serum thyroid peroxidase antibody level and incident hypertension in Iranian men: A suggestion for the role of thyroid autoimmunity
Maryam Tohidi, Aidin Baghbani-Oskouei, Atieh Amouzegar, Ladan Mehran, Fereidoun Azizi, Farzad Hadaegh
Endocrine Metabolic and Immune Disorders Drug Targets, 2020
Smoking status and changes in thyroid-stimulating hormone and free thyroxine levels during a decade of follow-up: The Tehran thyroid study
Hoda Kadkhodazadeh, A. Amouzegar, L. Mehran, Safoora Gharibzadeh, F. Azizi, M. Tohidi
Caspian Journal of Internal Medicine, 2020
Iranian endocrine society guidelines for screening, diagnosis, and management of gestational diabetes mellitus
Majid Valizadeh, Farhad Hosseinpanah, Fahimeh Ramezani Tehrani, Hengameh Abdi, Ladan Mehran, Farzad Hadaegh, Atieh Amouzegar, Farzaneh Sarvghadi, Fereidoun Azizi, and
International Journal of Endocrinology and Metabolism, 2020
Thyroid disease and the metabolic syndrome
Ladan Mehran, Atieh Amouzegar, Fereidoun Azizi
Current Opinion in Endocrinology Diabetes and Obesity, 2019
Long-Term Variations of Antithyroperoxidase Antibodies and its Clinical Significance
Masoumeh Keyhanian, Farzaneh Sarvghadi, Ladan Mehran, Atieh Amouzegar, Maani Beigy, Maryam Tohidi, Fereidoun Azizi
Hormone and Metabolic Research, 2019
Audit of the congenital hypothyroidism screening program in 15 Provinces of Iran
Archives of Iranian Medicine, 2019
Evaluation of the congenital hypothyroidism screening programme in Iran: A 3-year retrospective cohort study
Ladan Mehran, Davood Khalili, Shahin Yarahmadi, Hossein Delshad, Yadollah Mehrabi, Atieh Amouzegar, Nasrin Ajang, Fereidoun Azizi
Archives of Disease in Childhood Fetal and Neonatal Edition, 2019
Secondary and tertiary preventions of thyroid disease
Fereidoun Azizi, Ladan Mehran, Farhad Hosseinpanah, Hossein Delshad, Atieh Amouzegar
Endocrine Research, 2018
Subclinical thyroid dysfunction and incident cardiovascular disease: Tehran thyroid study
Iranian Journal of Endocrinology and Metabolism, 2018
Associations between Thyroid and Blood Pressure in Euthyroid Adults: A 9-Year Longitudinal Study
Hengameh Abdi, Safoora Gharibzadeh, Erfan Tasdighi, Atieh Amouzegar, Ladan Mehran, Maryam Tohidi, Fereidoun Azizi
Hormone and Metabolic Research, 2018
Tehran thyroid study (TTS)
Atieh Amouzegar, Ladan Mehran, Miralireza Takyar, Hengameh Abdi, Fereidoun Azizi
International Journal of Endocrinology and Metabolism, 2018
Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study
Maryam Tohidi, Arash Derakhshan, Samaneh Akbarpour, Atieh Amouzegar, Ladan Mehran, Aidin Baghbani-Oskouei, Fereidoun Azizi, Farzad Hadaegh
Hormone and Metabolic Research, 2018
Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study
Maryam Tohidi, Arash Derakhshan, Samaneh Akbarpour, Atieh Amouzegar, Ladan Mehran, Aidin Baghbani-Oskouei, Fereidoun Azizi, Farzad Hadaegh
Hormone and Metabolic Research Hormon Und Stoffwechselforschung Hormones Et Metabolisme, 2018
The impact of iodine status on the recall rate of the screening program for congenital hypothyroidism: Findings from two national studies in Iran
Ladan Mehran, Shahin Yarahmadi, Davood Khalili, Pantea Nazeri, Hossein Delshad, Zahra Abdollahi, Nasrin Azhang, Fereidoun Azizi
Nutrients, 2017
Primordial and primary preventions of thyroid disease
Fereidoun Azizi, Ladan Mehran, Farhad Hosseinpanah, Hossein Delshad, Atieh Amouzegar
International Journal of Endocrinology and Metabolism, 2017
Influence of topical iodine-containing antiseptics used during delivery on recall rate of congenital hypothyroidism screening program
Majid Valizadeh, Farzaneh Moezzi, Zohreh Khavassi, Mohammad Movahedinia, Seideh Mazloomzadeh, Ladan Mehran
Journal of Pediatric Endocrinology and Metabolism, 2017
Variations in Serum Free Thyroxine Concentration Within the Reference Range Predicts the Incidence of Metabolic Syndrome in Non-Obese Adults: A Cohort Study
Ladan Mehran, Atieh Amouzegar, Mahmood Bakhtiyari, Mohammad Ali Mansournia, Parnian Kheirkhah Rahimabad, Maryam Tohidi, Fereidoun Azizi
Thyroid, 2017
Association between Thyroid Function and Body Mass Index: A 10-Year Follow-Up
Hengameh Abdi, Elham Kazemian, Safoora Gharibzadeh, Atieh Amouzegar, Ladan Mehran, Maryam Tohidi, Zahra Rashvandi, Fereidoun Azizi
Annals of Nutrition and Metabolism, 2017
Natural Course of Euthyroidism and Clues for Early Diagnosis of Thyroid Dysfunction: Tehran Thyroid Study
Atieh Amouzegar, Zahra Ghaemmaghami, Maani Beigy, Safoora Gharibzadeh, Ladan Mehran, Maryam Tohidi, Fereidoun Azizi
Thyroid, 2017
Thyroid Function and Metabolic Syndrome: A Population-Based Thyroid Study
Ladan Mehran, Atieh Amouzegar, Parnian Rahimabad, Maryam Tohidi, Zhale Tahmasebinejad, Fereidoun Azizi
Hormone and Metabolic Research, 2017
The predictive value of metabolic syndrome for cardiovascular and all-cause mortality: Tehran Lipid and Glucose Study
Atieh Amouzegar, Ladan Mehran, Mitra Hasheminia, Parnian Kheirkhah Rahimabad, Fereidoun Azizi
Diabetes Metabolism Research and Reviews, 2017
The prevalence, incidence and natural course of positive antithyroperoxidase antibodies in a population-based study: Tehran thyroid study
Atieh Amouzegar, Safoora Gharibzadeh, Elham Kazemian, Ladan Mehran, Maryam Tohidi, Fereidoun Azizi
Plos One, 2017
Worldwide recall rate in newborn screening programs for congenital hypothyroidism
Ladan Mehran, Davood Khalili, Shahin Yarahmadi, Atieh Amouzegar, Mehdi Mojarrad, Nasrin Ajang, Fereidoun Azizi
International Journal of Endocrinology and Metabolism, 2017
The Association between Blood Pressure and Normal Range Thyroid Function Tests in a Population Based Tehran Thyroid Study
A. Amouzegar, M. Heidari, S. Gharibzadeh, L. Mehran, M. Tohidi, et al.
Hormone and Metabolic Research, 2016
Sex- and age-specific reference values and cutoff points for TPOAb: Tehran thyroid study
Atieh Amouzegar, Mahmood Bakhtiyari, Mohammad Ali Mansournia, Ali Etemadi, Ladan Mehran, et al.
Thyroid, 2016
Prevalent practices of thyroid diseases during pregnancy among endocrinologists, internists and general practitioners
Fereidoun Azizi, Ladan Mehran, Atieh Amouzegar, Shahram Alamdari, Imam Subetki, et al.
International Journal of Endocrinology and Metabolism, 2016
Maternal Thyroid Function and Autoimmunity in 3 Trimesters of Pregnancy and their Offspring's Thyroid Function
P. Sarkhail, L. Mehran, S. Askari, Z. Tahmasebinejad, M. Tohidi, et al.
Hormone and Metabolic Research, 2015
Association between thyroid hormones, thyroid antibodies and insulinresistance in euthyroid individuals: A population-based cohort
A. Amouzegar, E. Kazemian, S. Gharibzadeh, L. Mehran, M. Tohidi, et al.
Diabetes and Metabolism, 2014
Comparison of two guidelines on management of thyroid nodules and thyroid cancer during pregnancy
Archives of Iranian Medicine, 2014
Serum free thyroxine concentration is associated with metabolic syndrome in euthyroid subjects
Ladan Mehran, Atieh Amouzegar, Maryam Tohidi, Maryam Moayedi, Fereidoun Azizi
Thyroid, 2014
Prevention of iodine-deficiency induced goiter and brain damage in the Islamic Republic of Iran
Iranian Journal of Endocrinology and Metabolism, 2014
Prevalence of hypothyroidism in patients with dyslipidemia: Tehran Thyroid Study (TTS)
M. Khazan, A. Amouzegar, S. Gharibzadeh, L. Mehran, M. Tohidi, et al.
Hormone and Metabolic Research, 2014
Comparison of the American thyroid association with the endocrine society practice guidelines for the screening and treatment of hypothyroidism during pregnancy
Atieh Amouzegar, Ladan Mehran, Farzaneh Sarvghadi, Hossein Delshad, Fereidoun Azizi, et al.
Hormones, 2014
Local versus international recommended TSH references in the assessment of thyroid function during pregnancy
A. Amouzegar, E. Ainy, M. Khazan, L. Mehran, M. Hedayati, et al.
Hormone and Metabolic Research, 2014
Screening and management of hypothyroidism in pregnancy: Results of an Asian survey
Fereidoun Azizi, Atieh Amouzegar, Ladan Mehran, Shahram Alamdari, Imam Subekti, et al.
Endocrine Journal, 2014
Management of hyperthyroidism during pregnancy in Asia
Fereidoun Azizi, Atieh Amouzegar, Ladan Mehran, Shahram Alamdari, Imam Subekti, et al.
Endocrine Journal, 2014
Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: A population based study
Atieh Amouzegar, H Delshad, Ladan Mehran, Maryam Tohidi, Fatima M.Khafaji, et al.
Journal of Endocrinological Investigation, 2013
Iodine nutrition status and knowledge, attitude, and behavior in Tehranian women following 2 decades without public education
Parvin Mirmiran, Pantea Nazeri, Parisa Amiri, Ladan Mehran, Nezhat Shakeri, et al.
Journal of Nutrition Education and Behavior, 2013
Trimester-specific reference ranges for thyroid hormones in iranian pregnant women
Ladan Mehran, Atieh Amouzegar, Hossein Delshad, Sahar Askari, Mehdi Hedayati, et al.
Journal of Thyroid Research, 2013
Natural course of thyroid disease profile in a population in nutrition transition: Tehran thyroid study
Archives of Iranian Medicine, 2013
Erratum: Establishment of the trimesterspecific reference range for free thyroxine index (Thyroid (2012) 23 (354-359))
Thyroid, 2013
Management of hyperthyroidism in pregnancy: Comparison of recommendations of american thyroid association and endocrine society
Shahram Alamdari, Fereidoun Azizi, Hossein Delshad, Farzaneh Sarvghadi, Atieh Amouzegar, et al.
Journal of Thyroid Research, 2013
Management of thyroid peroxidase antibody euthyroid women in pregnancy: Comparison of the american thyroid association and the endocrine society guidelines
L. Mehran, M. Tohidi, F. Sarvghadi, H. Delshad, A. Amouzegar, et al.
Journal of Thyroid Research, 2013
Does a text messaging intervention improve knowledge, attitudes and practice regarding iodine deficiency and iodized salt consumption?
Ladan Mehran, Pantea Nazeri, Hossein Delshad, Parvin Mirmiran, Yadollah Mehrabi, et al.
Public Health Nutrition, 2012
Association between serum TSH concentration and body mass index in euthyroid subjects: The role of smoking
Archives of Iranian Medicine, 2012
The incidence of thyroid function abnormalities and natural course of subclinical thyroid disorders, Tehran, I.R. Iran
H Delshad, Ladan Mehran, Maryam Tohidi, Majid Assadi, Fereidoun Azizi
Journal of Endocrinological Investigation, 2012
Eighteen years of continuously sustained elimination of iodine deficiency in the Islamic Republic of Iran: The vitality of periodic monitoring
Hossien Delshad, Atieh Amouzegar, Parvin Mirmiran, Ladan Mehran, Fereidoun Azizi
Thyroid, 2012
The Association of cigarette smoking with serum TSH concentration and thyroperoxidase antibody
L. Mehran, A. Amouzgar, H. Delshad, F. Azizi
Experimental and Clinical Endocrinology and Diabetes, 2012
Appropriate iodine nutrition in Iran: 20 years of success
Acta Medica Iranica, 2010
Continuous adequate iodine supplementation in fars province: The 2007 goiter and urinary iodine excretion survey in schoolchildren
Iranian Journal of Medical Sciences, 2010
Sustainability of a well-monitored salt iodization program in Iran: Marked reduction in goiter prevalence and eventual normalization of urinary iodine concentrations without alteration in iodine content of salt
F. Azizi, L. Mehran, R. Sheikholeslam, A. Ordookhani, M. Naghavi, et al.
Journal of Endocrinological Investigation, 2008
Experiences in the prevention, control and elimination of iodine deficiency disorders: A regional perspective
F. Azizi, L. Mehran
Eastern Mediterranean Health Journal, 2004

Ladan Mehran

EDUCATION

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS